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Silver nanoparticles (AgNP) emerged as a promising reagent for cancer therapy with 
oxidative stress implicated in the toxicity. Meanwhile, studies reported cold atmospheric 
plasma (CAP) generation of reactive oxygen and nitrogen species has selectivity towards 
cancer cells. Gold nanoparticles display synergistic cytotoxicity when combined with CAP 
against cancer cells but there is a paucity of information using AgNP, prompting to 
investigate the combined effects of CAP using dielectric barrier discharge system (voltage of 
75 kV, current is 62.5mA, duty cycle of 7.5kVA and input frequency of 50-60Hz) and 10nm 
PVA-coated AgNP using U373MG Glioblastoma Multiforme cells. Cytotoxicity in U373MG 
cells was >100-fold greater when treated with both CAP and PVA-AgNP compared with 
either therapy alone (IC50 of 4.30 µg/mL with PVA-AgNP alone compared with 0.07 µg/mL 
after 25s CAP and 0.01 µg/mL 40s CAP). Combined cytotoxicity was ROS-dependent and 
was prevented using N-Acetyl Cysteine. A novel darkfield spectral imaging method 
investigated and quantified AgNP uptake in cells determining significantly enhanced uptake, 
aggregation and subcellular accumulation following CAP treatment, which was confirmed 
and quantified using atomic absorption spectroscopy. The results indicate that CAP 
decreases nanoparticle size, decreases surface charge distribution of AgNP and induces 
uptake, aggregation and enhanced cytotoxicity in vitro.  
 






Glioblastoma Multiforme (GBM) is an aggressive grade IV astrocytoma. It is the most 
dominant form of central nervous system malignancy, accounting for 47.1% of all tumours 
diagnosed in the CNS[1]. The current predominant treatment is surgical resection followed 
by radiotherapy and chemotherapy with Temozolomide[2]. However, conventional 
treatments are rarely successful and are plagued with poor target delivery, poor efficacy and 
systemic toxicity. Despite intensive therapeutic strategies and medical care, approximately 
5% of GBM patients survive five years after diagnosis[1].  In addition, more than 90% of 
GBM patients reveal recurrence at or near the primary site after treatment, underlining the 
need for a new effective therapeutic approach[3]. 
Nanoparticles (NP) have been used for therapy in diverse fields as a radiosensitiser[4], 
fluorescent labels[5], transfection vectors[6] and as drug carriers[7]. The size, shape and 
material composition confer advantageous properties on NP for various applications[8]. In 
particular, silver nanoparticles (AgNP) are the most widely used nanomaterial in consumer 
products such as household, cosmetics and healthcare-related products due to its 
antimicrobial properties through the release of silver ions[9]. The generation of reactive 
oxygen species has been associated with AgNP toxicity, making it useful for anticancer 
therapy[10]. Studies have shown that AgNP induce alterations in metabolic activity, cell 
morphology and decreased cell viability. Treatment with AgNP showed higher selectivity 
towards aggressive brain cancer human glioblastoma cells (U251) compared with a normal 
human lung fibroblast cells (IMR-90), leading to mitochondrial damage and increased in 
reactive oxygen production, resulting with DNA damage[11]. The combined NPs advantages 
of small size and large surface area has led to their use as drug delivery systems. In 
particular, AgNPs have attracted attention due to their intrinsic anticancer activity and 
effective drug delivery agents in previous studies[12–14]. Studies have shown AgNPs 
capability of crossing the blood brain barrier (BBB), providing opportunities and tackling 
challenges associated with NP drug delivery to the central nervous system (CNS)[15–17]. 
Recently, metal nanoparticles have been utilised to enhance cytotoxicity in cancer cells 
using oxidising treatments such as radiation therapy[18,19]. Liu, et al, demonstrated AgNP 
outperforming gold nanoparticles (AuNP) in radiosensitising glioma cell line U251, where 
combination of AgNP and radiotherapy showed significant anti-glioma effect in vitro and in 
vivo in comparison to AuNP[4]. These studies resulted to multitude applications of employing 
NPs to cancer treatments through a vast number of strategies. 
 
More recently, plasma treatment has shown potential as a future cancer therapy. Plasma is 
the fourth state of matter next to solid, liquid and gas. It can be artificially produced for its 
versatile applications[20]. Plasmas are classified as either thermal or non-thermal, also 
known as cold atmospheric plasma (CAP). The non-thermal nature of CAP coupled with a 
wide range of biological effects has led to the emergence of CAP across a range of 
biomedical applications including wound healing, dentistry and sterilisation[21]. CAP has low 
power requirements and is achieved at low or atmospheric pressure. CAP provides a rich 
environment of reactive oxygen species (ROS) such as singlet oxygen (1O2), superoxide 
(·O2
-), ozone (O3), hydroxyl radicals (·OH), hydrogen peroxide (H2O2) and generates reactive 
nitrogen species (RNS) such as nitric oxide (·NO) nitrite and nitrate anions (NO2 and 
NO3)[22]. Recent studies have shown CAP’s potential application in cancer therapy with 
biochemical features of cancer cells including high levels of ROS due to oncogenic 
transformation and with the application of CAP triggered self-perpetuating process of RONS 
induction, which  effectively showed to induce apoptosis selectively against cancer cells 
overcoming the problem with conventional treatments[23]. In contrast to NPs systemic 
application, the effects of CAP are mostly associated with the location of treatment with few 
systemic effects observed and hence the recent trend in research of CAP is the interaction 
at cellular level [24]. The localised interaction of CAP with mouse fibroblast cells, BEL-7402 
liver cancer cells and PAM212 cancer cells demonstrated detachment from extracellular 
matrix when treated[25]. CAP’s ability to change biochemical signalling intracellularly without 
thermal and electrical damage creates a suitable biomedical application[26]. The operating 
system of plasma discharged used in this study is the dielectric barrier discharge (DBD), DIT 
120, which generates high voltage output of non-thermal plasma between two aluminium 
electrodes[27]. CAP induced by the DIT 120 system has previously been reported to induce 
cell death at higher exposures and enhance uptake of gold nanoparticles at lower exposures 
in U373MG glioblastoma multiforme cancer cells, the cell line used in this study[28,29]. 
A synergistic cytotoxic effect has been reported when CAP and various nanoparticles are 
combined, as first reported in 2009 by Kim, et al.,  who found a 5-fold increase in cytotoxicity 
on G361 melanoma cancer skin cells when treated with ambient air CAP combined with 
antibody-conjugated AuNP [30]. Since then, studies using nanomaterials with various sizes 
and compositions have been used. For example, electrosprayed core-shell nanoparticle 
fabricated with 5- Fluorouracil synergistically inhibited cell growth of epithelial breast cancer 
cells MBA-MD-231 when used with CAP[31]. The plasma jet device using helium and 
oxygen gas in combination with Iron NPs significantly decreased viability of human breast 
adenocarcinoma cancer cells, MCF-7[32]. Our own group unveiled 25-fold enhanced 
cytotoxicity on U373MG cells when 20 nm citrate-capped AuNP were combined with non-
toxic doses of CAP, demonstrating enhanced AuNP endocytosis and subcellular 
trafficking[29]. Meanwhile, interest in AgNP has shifted beyond antimicrobial use to potential 
additional anticancer applications[33–35]. Evidence is emerging that oxidative stress 
induced by low dose AgNP is implicated in their cytotoxicity[36–39]. Despite AgNP being the 
main commercial nanomaterial used worldwide, there are limited reports on combining AgNP 
with other current therapies to investigate its possible enhanced effect in comparison to 
various type of nanoparticles studied.  
In consideration of the advantages of both AgNP and CAP, the importance of oxidative 
stress in both modes of cytotoxicity, the enhancement of AgNP toxicity when combined with 
other oxidising treatments and the finding that CAP can induce cellular uptake of 
nanomaterials, we chose to investigate whether synergistic cytotoxicity exists between AgNP 




All chemicals used were obtained from Sigma-Aldrich (Vale Road, Arklow, County Wicklow, 
Ireland) unless specified otherwise.  
 
Cell culture 
Human Glioblastoma Multiforme cells U373MG-CD14, (ECACC 09063001; U-251 MG, 
formerly known as U-373 MG) derived from a malignant tumour were obtained from Dr. 
Michael McCarthy (Trinity College Dublin)[40]. U373MG cells were maintained in DMEM/F-
12 Ham (Sigma-Aldrich, D8062) and were supplemented with 10% v/v foetal bovine serum. 
The cell line was incubated at 37°C and 100% humidity containing 5% CO2. U373MG were 
sub-cultured at 70-80% confluency using 1:1 ratio of 0.25% trypsin (Gibco by Life 




The top-down synthesis used in the study was previously reported by Mavani et al[41]. Cold 
synthesis was employed with chemical reduction of silver nitrate (AgNO3) of 0.001M with ice-
cold reducing agent sodium borohydride (NABH4) of 0.002M in the presence of a stabiliser 
formed AgNP. 2ml of 1% polyvinyl alcohol (PVA) in millipore water (Simplicity 185, 18.2 
MΩ.cm at 25°C resistivity) was added with 2ml of silver nitrate and mixed well[42]. The ice-
cold reducing agent was stirred for 20 minutes and 2 ml of mixed AgNO3/PVA were added 1 
drop per second approximately and reaction was stopped. PVA stabilised silver 
nanoparticles (PVA-AgNP) mixture was concentrated by using an ultrafiltration tube of 3kDa 
(Sartorius, UK) with centrifuge, Heraeus Megafuge 16R (Thermo Scientific) at 5000 rpm. 
PVA-AgNP were stored away from direct exposure to light at 4ºC. The chemical reduction of 
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AgNP characterisation 
The primary characterisation of synthesised PVA-AgNP was achieved by Ultra-Violet 
Spectroscopy (UV-Vis) (Shimadzu, UV-1800) and the stability of PVA-AgNP prepared were 
observed for 6 months. Dynamic Light Scattering (DLS) was used to measure the 
hydrodynamic diameter (Dh) and zeta potential of PVA-AgNP (Malvern Instruments, UK). 
The size, shape and morphology of PVA-AgNP was assessed by scanning transmission 
electron microscopy (STEM) (Hitachi SU 6600) with 3µl of PVA-AgNP aqueous solution 
placed on a carbon-coated copper grid and the samples were allowed to dry to obtain the 
highest yield of particles on the grid. PVA-AgNP concentration measurements were 
performed by atomic absorption spectroscopy (AAS) using (Varian SpectrAA 200) against 
Ag calibration standard at 1, 2, 3, 4, 5 µg Ag/ml prepared from 1 g/L standard. AgNP 
samples were prepared by 1/10 dilution by adding 1ml concentrated PVA-AgNP to 9 mL of 
millipore water.  
 
Cold atmospheric plasma device 
The CAP system used was a dielectric barrier discharge (DBD) device. It is a novel 
prototype atmospheric low temperature plasma generator[27]. The CAP-DBD is composed 
of a variable high voltage transformer with an input voltage of 230 V at 50 Hz and a 
maximum high voltage output of 120kV. It consists of two 15-cm-diameter aluminium disc 
electrodes, separated by 26.6 mm and a 1.2mm thick polypropylene sheet which is used as 
a dielectric barrier and platform for holding cell samples. The voltage was monitored using 
an InfiniVision 2000 X-Series Oscilloscope (Agilent Technologies Inc., Santa Clara, CA, 
USA). DIT-120 is calibrated on a yearly basis. There is a rebuild of the system in which the 
generated ozone and ROS produced are regularly compared to identify the time exposure to 
give the equivalent dose and effect in the study. 
Cell viability assay 
Alamar Blue was used as a parameter for measuring cytotoxicity[28,43]. Alamar blue assay 
was analysed according to manufacturer’s protocol (Invitrogen by Thermo Fisher Scientific, 
USA). Firstly, U373MG cells (1x104 cells per well) were seeded into 96-well plates and 
allowed to adhere overnight. After seeding, 100µl of various concentration with 1:3 serial 
dilution of PVA-AgNP in DMEM were added between 0 µg/ml and 17.54 µg/ml. 1mM H2O2 
was used as a positive control for all cell viability assays. GBM cells were preloaded with 
PVA-AgNP for 24 hrs to allow maximum uptake of AgNP with low doses in cells, the cells 
were then exposed to CAP from 0-80s at 75kV as outlined above. For U373MG exposure to 
CAP, culture media was removed prior to CAP exposure leaving 10 µl of existing culture 
media with AgNP in 96 well plates and 500 µl of existing culture media containing AgNP in 
60mm petri dishes to avoid sample drying. Fresh culture media without AgNP was added 
immediately after exposure to CAP with a total of 100 µl in 96 well plates and 3 ml in 60mm 
petri dishes. The plates were incubated for a total of 48h post CAP treatment at 37°C. Cells 
were then washed with PBS and 10% Alamar blue was added into the wells for 3h at 37°C. 
The fluorescence was measured using excitation wavelength of 530nm and emission 
wavelength of 590nm on plate reader (SpectraMax M3, Molecular Devices (UK) Ltd). The 
protective effect of N-Acetyl Cysteine (NAC) was evaluated by pre-treating 4mM NAC on 
U373MG cells for 1h followed by treatment of PVA-AgNP at stated concentrations for 24h 
and exposed to CAP at 0s, 25s and 40s for another 24h. 
 
Flow Cytometry Analysis 
Propidium iodide (PI) was used to demonstrate live and dead cell staining with flow 
cytometer BD Accuri C6 (BD, Oxford, UK). U373MG cells were seeded in 6-well plate at 2.5 
x 105 cells per well and was incubated at 37ºC overnight to allow adherence. Cells were 
treated with PVA-AgNP at low-nontoxic dose of 0.07µg/mL for 24h and were exposed to 
CAP at 75kV for another 24h. Cells were harvested including pre-existing media and 
centrifuge to form a pellet. The pelleted cells were resuspended in 1ml PBS and was stained 
with PI for 1 minute with concentration of 10µg/mL. PI fluorescence was detected using FL2 
vs FSC demonstrating binding of PI to nuclear degradation from dead cells. 
H2DCFDA (Thermo Fisher Scientific) was used to measure ROS production induced by 
AgNP-CAP using flow cytometry. The cells were rinsed with PBS twice and incubated with 
25µM of H2DCFDA in the dark with serum-free media for 30 mins at 37ºC. U373MG cells 
were treated with low dose of PVA-AgNP of 0.09µg/mL for 24h an exposed to CAP. DCF 
fluoresce was immediately measure after CAP exposure using BD Accuri flow cytometer 
with filters count vs FL1. 
 
Measurement of CAP effect on AgNP size 
The effect of CAP on PVA-AgNP size was measured as follows: concentrated PVA-AgNP 
obtained from ultrafiltration to remove excess unwanted reactants including NaBH4 was 
resuspended in millipore water, in synthesis solution containing unwanted reactants and 
resuspending concentrated PVA-AgNP in 4mM NaBH4. The samples were exposed to CAP 
at different exposure times from 0-80s. The hydrodynamic size of the NPs was determined 
using DLS, Zetasizer Nano ZS. The morphology was determined using STEM (Hitachi SU 
6600), as described above. 
 
Darkfield spectral imaging of AgNP uptake: image acquisition and uptake analysis  
Optical observation of AgNP uptake was performed using darkfield spectral imaging (SI). 
The darkfield microscopy system utilised in this study consists of a  darkfield microscope 
(BX51, Olympus, Ltd) coupled to a Vis-NIR spectrograph (ImSpector V10E, Specim Ltd) and 
a Pelier cooled CCD detector, combined with a metal halide light source, liquid light guide 
and Cytoviva optical illuminator (CytoViva Inc., Auburn, AL, USA) and a motorised XY stage 
controller Images were obtained using a 100X oil immersion objective and oil immersion 
swing condenser.  
Detection and confirmation of AgNP uptake were determined by spectral mapping, using 
samples of fixed U373MG cells alone (38 images from slides), cells treated with AgNP (42 
images from slides), cells treated with CAP (42 images from * slides) and cells treated with 
combined AgNP-CAP (50 images from slides). U373MG cells were fixed by 4% 
paraformaldehyde on cover glass slip mounted with Mowiol 4-88 onto a rectangular cover 
glass slide (Corning cover glass, Sigma-Aldrich). Images were obtained over a time period of 
10 weeks as each image took approx. 15 minutes to obtain. 
The spectral images were acquired using ENVI 4.8 software and analysed using MATLAB 
(MATLAB R2019a, The MathWorks Ltd) functions written in house and from the image 
processing toolbox.  
False colour red-green-blue (RGB) images were constructed from the spectral images by 
assigning the following wavebands to each channel: 
Red: calculate mean image of waveband channels from 516 – 552 nm and scale to intensity 
values between 0-2000. 
Green: calculate mean image of waveband channels from 544 – 618 nm and scale to 
intensity values between 0-2000. 
Blue: calculate mean image of waveband channels from 704 – 735 nm and scale to intensity 
values between 0-2000. 
PCA was applied to the false colour images to create a mask between the cell and 
background (thresholding the first principal component score image such that all pixels with 
a values below 2 were set to one provided sufficient separation between cells and 
background). In some cases, multiple cells were attached to each other in the mask images. 
In order to be able to analyse each cell individually, these cells were separated manually by 
drawing a line across the narrowest connecting point in the mask image. In addition, some 
cells were only partially represented in a given field of view – such cells were removed from 
the analysis. Further, some pixels that were not identified as cells were highlighted in the 
mask – in order to remove them from the analysis, any regions with a pixel size smaller than 
300 pixels were automatically removed from the analysis. 
Standard normal variate pre-processing (i.e. subtracting the mean from each spectrum and 
dividing by the standard deviation) was applied to spectra and a partial least squares 
discriminant analysis model was developed to discriminate between NPs and cells. This 
model was subsequently applied to all images, facilitating identification of NPs from their 
spectra. Using the ‘regionprops’ function of the MATLAB image processing toolbox, the size 
and circularity of each cell and number and size of NPs per cell was calculated. The median 
number of NPs identified per cell was then calculated for each treatment. 
 
AAS measurement of AgNP uptake 
Atomic Absorption Spectroscopy (AAS) was further employed to measure uptake of AgNP. 
U37MG cells were grown in petri dishes with cell density of 2.5 x106 cells per dish. The 
samples were negative control with U373MG cells alone, cells treated with AgNP, cells 
exposed to CAP, the combined therapy on U373MG cells and positive control treated with 
1mM H2O2. The cells were treated with AgNP for 24h and after with 25s CAP for another 
24h. The cell samples were trypsinised and resuspended in the existing culture media. The 
samples were then analysed by AAS for AgNP detection. Triplicate readings were analysed 
for each sample and the results were expressed as the mean amount of Ag in pg/cell. 
Statistical analysis 
The data of the experiments are expressed as mean ± standard deviation of replicates from 
at least three independent experiments, unless specified otherwise. Statistical analysis and 
curve fitting presented in results were completed using Prism 7 (GraphPad Software). 
Analysis of data distribution was performed using two-way ANOVA and three-way ANOVA 
where indicated to analyse the differences of significance between the control group and 
treated groups. The following P values were deemed statistically significant, **P<0.01, 
***P<0.001, ****P<0.0001. Therapeutic synergism between PVA-AgNP and CAP was 
evaluated using isobologram analysis. CompuSyn software determined the combinational 
index (CI) where, CI>1 is antagonism, CI=1 is additive and CI<1 is synergism. Descriptive 
statistics (median, standard deviation) were calculated on cell size, circularity, NP size and 
number as derived from spectral imaging measurements.  
 
Results 
Silver Nanoparticles Characterisation 
 
Figure 1. Characterisation of Silver Nanoparticles (AgNP). (A) Representative scanning 
transmission electron microscopy images of AgNP was spherical in shape and well dispersed in 
aqueous solution. (B) Representation of AgNP maximum absorbance by UV-Visible spectrum of 
stable aqueous AgNP mixture observed for 6 months. (C, D) Size distribution measurement of stable 
PVA-AgNP for six months by dynamic light scattering 10.68 ±1.98nm to 9.59 ±2.52nm.  
PVA-AgNP were prepared and characterised as indicated in the methods section. STEM 
analysis of PVA-AgNP confirmed production of nanoparticles that are spherical in shape, 
approximately 10nm in size and well dispersed (see Figure 1a). The presence of a plasmon 
absorption band (400 nm), which is a main characteristic of AgNP, was evident and 
remained relatively unchanged over 6 months indicating the production of highly stable 
AgNP (see Figure 1b)[44]. The particle size range by DLS analysis was determined to be 8-
12 nm with an average of 10.68 ± 1.98 nm diameter size on first synthesis and after 6 
months of 9.59 ± 2.52 nm (see Figure 1c and 1d). PVA-AgNP polydispersity index (PDI) at 
first synthesis was 0.415 and after 6 months of 0.155, which is deemed acceptable with ISO 
standard document 22412:2008 with data remaining between the acceptable PDI range 
values of 0.05 to 0.7. 
 
Cytotoxic Effect of AgNP in Combination with CAP on Cellular Viability 
Cytotoxicity was examined using Alamar Blue and propidium iodide. U373MG cells were first 
treated with different concentrations of PVA-AgNPs (0-17.54 /) in combination with 
CAP (0-40s at 75kV) and incubated for 48 hours prior to measuring viability using Alamar 
blue (see Figure 2a). The cell viability decreased in a dose-dependent manner after AgNP 
treatment alone with IC50 of 4.730 µg/mL (95% confidence range from 3.094 to 6.084 
µg/mL). From previous work with the same DBD prototype used in this study, it was 
determined that the IC50 with CAP treatment alone is 74.26s (95% confidence range of 
47.24-116.8s) on U373MG cells[28]. In the current study, we combined treatment of AgNP 
with a range of low CAP exposures (i.e. 5s, 10s, 25s and 40s at 75kV). We found that cells 
displayed significant cytotoxicity with IC50 of 0.079 µg/mL and 0.01 µg/mL when treated with 
CAP for 25s and 40s respectively (95% confidence range from 0.0539 to 0.1139 µg/mL for 
25s and 0.0069 to 0.0138 µg/mL for 40s) (see Figure 2a). Two-Way ANOVA with Tukey’s 
multiple comparison post hoc test in figure 2b confirmed significant decrease in IC50 values 
caused by 25s and 40s CAP exposure (see Figure 2c, **P<0.01, ***P<0.001, ****P<0.0001). 
The combined AgNP and CAP treatment exhibited 67-fold increase in cytotoxicity (IC50) 
when combined with 25s CAP and greater than 100-fold increase in cytotoxicity (IC50) with 
40s CAP, which indicates a beneficial combinational anti-cancer therapy. This shows an 
enhanced toxic effect on U373MG cells when treated with combined therapy than with AgNP 
or CAP alone. No enhanced cytotoxicity was noted for 5s or 10 s doses with CAP in 
combination with AgNP, suggesting synergistic cytotoxicity only occurs between a minimum 
and maximum threshold dose for CAP. The isobologram on figure 2c determined the 
synergistic effect of PVA-AgNP combined with CAP resulting to combination index value (CI) 
of less than 1.00. The CI of PVA-AgNP with 25s CAP is 0.35 and 0.54 with 40s CAP. PVA-
AgNP with shorter CAP exposure time resulted to CI of 0.93 and 0.96 with 5s CAP and 10s 
CAP respectively suggestive to an additive effect.  
 
Figure 2. Synergistic Cytotoxicity of combined AgNP with Cold Atmospheric Plasma (CAP). (A) 
Combinational therapy effect of AgNP with CAP on U373MG cells. Cells were treated with different 
concentration of AgNP for 24h followed by different time exposure with CAP at 75kV. Untreated GBM 
cells are used as negative control and cells treated with 1mM H2O2 was used as positive control. (B) 
Heat map representation of results from Figure 2A, showing the darkest region with the least viable 
cell to the lightest region with the most viable cell from combinational AgNP with CAP at different time 
exposure. Statistical analysis carried out using two-way ANOVA for Figure 2A, two-way ANOVA with 
Tukey’s multiple comparison post-test (**P<0.01, ***P<0.001, ****P<0.0001). All experiments were 
repeated at least three times. (C) Isobologram analysis of the combinational effect of AgNP-CAP. The 
single doses CAP on y-axis and AgNP on x-axis were used to draw the line of additivity. The 
localisation of combined AgNP-CAP at different time exposures can be translated to synergism CI<1, 
additivity CI=1 or antagonism C1>1. (D) Apoptotic nuclear membrane degradation was validated for 
the combined PVA-AgNP and CAP at 75kV using propidium iodide (10µg/ml) with flow cytometry. The 
represented data was normalised to the negative control and is displayed as %mean ± SD (n=3). 
 
GBM cells treated with plasma activated AgNP solution was explored, which is an off-site 
treatment where the NP solution is exposed to the plasma source for a pre-determined time 
and in this case for 25s CAP exposure. Due to previous reports on plasma activated liquids 
(PAL) showing effectivity against cancer cells after duration of storage, the current study 
explored the efficacy of PAL with AgNP on GBM cells. As can be seen in supplementary 
data file in supplementary figure 1, pre-CAP exposure on AgNP and treated on GBM cells 
displayed cytotoxic effect but not as significant with the original method of on-site CAP 
treatment. Plasma activated AgNP treated GBM cells has IC50 value of 1.549 µg/ml and was 
deemed not as significant (P<0.05) in comparison with the technique applied for figure 2b 
(P<0.0001).  
The enhanced cell death was confirmed and quantified by employing propidium iodide with 
flow cytometry. Figure 2d demonstrates the enhanced uptake of PI with the combined 
therapy of PVA-AgNP and CAP, in which PI has bound to the nucleic acids within the 
nucleus of AgNP-CAP treated GBM cells and compared to the negative untreated control. 
The size and granularity of dying cells changes, where dead cells are smaller and more 
granular resulting in high PI fluorescence in FL2 and live cells are larger and less granular 
resulting in low PI fluorescence as can be seen in the dot plot of figure 2d with FL2 in log 




ROS Detection Induced by AgNP-CAP 
The main component of CAP is the generation of RONS and many have linked oxidative 
stress with AgNPs toxicity in previous studies[36–39]. NAC is a scavenger of oxygen-free 
radicals and directly interacts with reactive ionised species. The protective effect of NAC on 
AgNP and in combination with CAP can be seen in figure 3a. The IC50 value for AgNP 
control was 4.9 µg/ml with 95% confidence range of 3.759 to 6.081µg/ml. The IC50 value for 
AgNP with pre-treated NAC was 6.57 µg/ml with 95% confidence range of 5.989 to 7.130 
µg/ml. The IC50 value for the combinational AgNP-CAP without NAC at 25s was 0.06 µg/mL 
(95% confidence range of 0.0355 to 0.112 µg/mL), whereas a 10-fold decrease in toxicity 
was observed when cells were pre-treated with NAC with IC50 of 0.7
 µg/mL (95% confidence 
range of 0.383 to 1.655 µg/mL). Three-Way ANOVA with Tukey’s multiple comparison post 
hoc test in figure 3b confirmed to be statistically significant (see figure 3b, **P<0.01, 
***P<0.001, ****P<0.0001).  
 
 
Figure 3. Protective effect of NAC. (A) Pre-treatment of N-Acetyl-L-cysteine (NAC) showed 
protective effects against AgNP combined with CAP after 48h using Alamar Blue assay. (B) Heat map 
interpretation of protective effects of NAC on combined therapy with the lighter the colour the more 
viable cells and the darker the heat map with less viable cells. Statistical analysis carried out on data 
presented in figure 3A using three-way ANOVA for 2C and 2D with Tukey’s multiple comparison post-
test (**P<0.01, ***P<0.001, ****P<0.0001). All experiments were repeated at least three times. (C) 
Representation of the significant production of ROS by PVA-AgNP combined with CAP that is 
statistically significant according to Tukey’s test, one-way ANOVA (*P<0.05, **P<0.01, ***P<0.001, 
****P<0.0001). 
 
The protective effect of ROS-scavenger, NAC was validated when production of ROS by the 
combined therapy was explored. H2DCFDA a fluorescent probe was used to measure ROS 
production induced by AgNP-CAP. In presence of ROS, the non-fluorescent H2DCFDA is 
converted to the highly fluorescent DCF, which was observed with the combination therapy 
of PVA-AgNP with CAP. Figure 3c shows AgNP-CAP resulted to higher ROS levels in 
comparison to AgNP alone at low dose and CAP alone for 50s at 75kV when compared to 
the untreated control. The differences between the test were examined by Tukey’s multiple 
comparison test, one-way ANOVA, where statistically significant tests were presented as 
**P<0.01, ***P<0.001, ****P<0.0001 in figure 3c. 
 
The effect of CAP on AgNP size 
Our data indicate that ROS-dependent cytotoxicity is induced in GBM cells treated with a 
combination of CAP and AgNP. The toxicity is likely due to one or more of the following: 
cellular rate of uptake, increase in cell membrane permeability, changes to nanoparticle size 
and morphology, altered dispersion or agglomeration and rate of dissolution. It has been 
reported that NPs can be prepared using an electrical discharge[45–47]. We therefore 
investigated the effect of CAP on AgNP. 10nm freshly synthesised AgNP including unwanted 
reactants in the existing solution containing excess NaBH4 (4mM) were exposed to the DBD-
CAP device (75kV, 0-80s). The size of AgNP significantly decreases in a dose-dependent 
manner when exposed to CAP (Figure 4a). In contrast to this, purified AgNP resuspended in 
fresh millipore water without unwanted reactants with CAP did not change significantly in 
size. We confirmed this using STEM. AgNP in a solution of the reductive agent, NaBH4 
(4mM) showed decrease in size (5 nm) when exposed to 25s CAP compared with controls 
without CAP treatment (10 nm) (see Figure 4b). Nanoparticle morphology and dispersion did 
not change during CAP exposure, and AgNP remained spherical in shape, uniformly 
dispersed with no visible aggregation in the samples was observed.  
 
 
Figure 4. Comparative Results on the Effect of CAP on AgNP Physical Properties. (A) Overview 
of PVA-AgNP size change with different time exposure to CAP with and without presence of reductive 
agent. Data represented mean ± standard error of the mean (n=9). (B) STEM images displaying size 
variation of AgNP in aqueous solution without CAP exposure and 25s exposure with CAP at 75kV. (C) 
Zeta potential of AgNP before and after CAP treatment in millipore water (mH2O), in presence of 
100µM H2O2 and culture media (DMEM). Representation of zeta potential of AgNP before CAP 
treatment with -55.6 ±8.06mV to -26.8 ±9.08mV after 25s CAP exposure in mH2O and -18.0 ± 8.70mV 
without CAP exposure to 11.40 ± 5.06mV after CAP exposure at 75kV in culture media. 
 
The recognised value for zeta potential that is anything higher than positive or negative 
30mV is a stable suspension[48]. Figure 4c shows an electrostatically stabled nanoparticle 
suspension of -55.6 ± 8.08mV with conductivity of 0.360mS/cm and after CAP exposure of 
25s the nanoparticle suspension has zeta potential of -26.80 ± 9.08mV with conductivity of 
0.25mS/cm for PVA-AgNPs suspended in millipore water. The production of ROS, H2O2 by 
DIT-120 was examined by our group previously to generate 100µM in 60s[49]. The change 
of zeta potential on AgNP were explored with the presence of 100 µM H2O2 in mH2O and 
have shown to change the zeta potential to -20.4 ± 8.03mV (figure 4c). In contrast to PVA-
AgNP in millipore suspension, PVA-AgNPs in culture media (DMEM-F12) has changed the 
zeta potential value of -18.0 ± 8.70mV with conductivity of 0.011mS/cm and after CAP 
exposure of PVA-AgNP in DMEM-F12 the zeta potential decreased further to -11.40 ± 
5.06mV with conductivity of 0.30mS/cm. The statistical difference between zeta potential test 
with CAP exposure and resuspended in DMEM have deemed to be statistically significant 
when compared to AgNP in mH2O (**P<0.01 and ***P<0.001). The difference between zeta 
potential test of AgNP in DMEM and AgNP in DMEM exposed to CAP resulted as not 
significant according to Tukey’s one-way ANOVA comparison post hoc test (P>0.05). The 
change of zeta potential of NPs was previously reported in other studies that affects the 
internalisation process during uptake of NPs by cells. Uptake of PVA-AgNP was further 
explored and can be seen in figure 5. 
 
Uptake of AgNP in U373MG cells 
The study further investigated whether the significant difference on cytotoxicity of AgNP 
treated alone compared to combination of AgNP-CAP could be explained by differences in 
cellular uptake and localisation intracellularly. Visualisation of cell morphology, nanoparticle 
distribution and particle localisation after treatment with low dose of 0.07 µg/ml AgNP alone 
and in combination with 25s CAP at 75kV was investigated using Spectral imaging (SI) at 
60X oil immersion (see Figure 5a). SI offer quantitative analysis capturing both biological 
and materials at nanoscale level. The classification tools with dominant spectral signatures 
enables to characterise nanoparticles in populations and individually and morphology of cells 
prior and after treatment. Figure 5a shows images of in-vitro cells with false RGB setting 
derived from SI Cytoviva and a comparison mathematical modelling analysed from Matlab 
viewing cell morphology of brain cancer cells U373MG without NP treatment showing a 
healthy astrocyte-shaped cells, followed by U373MG remaining its healthy astrocyte-shape 
treated with low dose of PVA-AgNP present, cells treated with CAP for 25s showing cellular 
stress with morphological changes losing the astrocyte shape with no NPs evident and the 
combination therapy of AgNP-CAP presenting cell disruption and increase of PVA-AgNP 
visible in the cells. The comparison of the mathematical with false-RGB images allows to 
visualise and localise PVA-AgNP present in U373MG cells when treated. A library of spectra 
was derived from the scattered light of cells and PVA-AgNP identifying unique spectral 
signatures that is highly repeatable in approx. 50 images per sample (see Figure 5a). The 
spectral profile is graphed as wavelength (nm) versus intensity of scattered light (a.u.) 
presenting spectral signatures and interaction of NPs to cells with spectral response showing 
a broad scattering spectrum of U373MG cells alone are at 520nm with low intensity, PVA-
AgNPs spectral response in cells is at 520nm with higher intensity and an enhanced 
intensity of PVA-AgNP when exposed to CAP showing a shift of the resonance peak to 
570nm represents NPs aggregating into larger sizes. Previous study have shown shifting of 
spectral peak is suggestive to agglomeration in suspension and in cells and also change in 
NP physical property such as zeta potential is also suggestive to agglomeration[50,51]. SI 
allows to quickly identify, map PVA-AgNP present in cells and provide class distribution 
confirming the total number and size of NPs in cell. Figure 5b displays NPs class distribution 
with only the combination therapy of AgNP-CAP detecting median number of 47 NPs per cell 
with standard deviation of 84.42 NPs and a median NP size of 8nm with standard deviation 
of 9.7nm. However, numerical data derived from analysis of spectral images should be 
considered approximate, as threshold is applied to disregard any NPs <2 pixels in size (see 
supplementary data for figure 5b) since light scattering from different cellular compartments 
may hinder thorough viewing or may cause false positive detection of NPs as can be seen in 
figure 5b with negative control and the higher signal detected in CAP samples is due to the 
effect of CAP on U373MG morphology, losing GBM’s healthy astrocyte shape to a damaged 
circular shape intensifying the light scatter of cellular compartments (see figure 5a).  The 
data shown in figure 5b was normalised to the untreated negative control and represented 
as %median ± S.E.M. To further verify the uptake of AgNP as observed from SI, the cellular 
dose of AgNPs in U373MG cells was quantified using Atomic Absorption Spectroscopy. The 
mean concentration of Ag per cell was observed to be 0.030 pg Ag/ cell for AgNP treatment 
alone (95% confidence range of 0.022 to 0.083 pg Ag/ cell) and 0.89 pg Ag/ cell for 
combined therapy AgNP-CAP (95% confidence range of 0.50 to 1.28 pg Ag/ cell) (see 
Figure 2d). The data presented in figure 5c is displayed as %mean ± SD.  This correlates 
with our previous study (He et al) when we found that combination of gold nanoparticles with 
CAP increased nanoparticle uptake[29]. 
 
 
Figure 5. Uptake and Dissolution of AgNP by CAP. (A) Spectral imaging of mapped GBM cells 
presenting PVA-AgNP treated alone with magenta pixels and the combined AgNP-CAP with red 
pixels in GBM cells in blue pixels. The scale bar for RGB images is 21.5µm. Representative spectral 
response of GBM cells (blue), background (black), PVA-AgNP (magenta) in cells and the combined 
treatment of AgNP-CAP (red). (B) Representation of SI analysis on quantifying median number of 
AgNP/cell with only the combined therapy of AgNP-CAP resulted to 47 NPs per cell. Data shown was 
normalised to the negative untreated control and is shown as %median ± S.E.M. (n=3) (C) AgNP 
uptake before and after CAP treatment was confirmed and quantified using AAS. The mean 
concentration of silver per cell was 0.030pg Ag/cell for PVA-AgNP treatment alone and 0.89pg Ag/cell 
for combined treatment of AgNP-CAP. The represented data was normalised to the negative control 
and is displayed as %mean ± SD (n=3).   
 
Discussion  
The advancement of nanotechnology and plasma medicine in biomedical applications tackle 
the same set of challenges but have been developed independently and often along different 
routes. The similarities and contrast of nanoparticles and cold atmospheric plasma have 
scoped their intriguing predetermined therapeutic use, particularly the selectivity against 
cancer cells with the selective application process of CAP as well as functionalising 
nanoparticles for targeted delivery to cancer cells, chemical reactivity through generation of 
ROS by CAP and AgNP, finally the safety to healthy cells and tissue. Concurrently, synergy 
captured from the combination of nanoparticle and cold atmospheric plasma with recent 
studies including gold nanoparticles, iron nanoparticles and drug-loaded core shell 
nanoparticles with cold atmospheric plasma have demonstrated highly promising benefits for 
medicine[23,27–29]. Despite the reports of CAP sensitivity to cancer cells, we and others 
have demonstrated that the Glioblastoma multiforme cell line U373MG is relatively resistant 
to CAP treatment[28] and approaches to overcome this inherent resistance will be necessary 
in a clinical setting. In addition, with the ever-growing interest of combined cancer therapy 
with nanotechnology and plasma medicine, the combination of AgNP with CAP has not yet 
been reported. In this study, the combined synergistic effect of PVA stabilised AgNP with 
CAP on U373MG was evaluated and the interaction between CAP and AgNPs physical 
properties and its effect on cell morphology were demonstrated. 
The restrictive approach in this study focuses on strategic minimal dosing of AgNP in 
combination with CAP to achieve a targeted cytotoxic effect on Glioblastoma cell line 
U373MG. NPs physico-chemical characteristics and their effects play a major role on 
biological systems, where NPs are reported to penetrate and accumulate in different tissues 
showing high mobility. The shape, morphological structure and size are the principal 
parameters of NPs along with its chemical composition and its inherent toxicological 
properties[8,52]. Consequently, the characterisation of NPs physical properties is key to 
compare its biological and toxicological response. In this study, an in-house synthesised 
spherical AgNP stabilised with PVA with size 10.68 ± 1.98 nm showed high stability in 
aqueous solution for six months, which is in agreement with previous studies on size-
controlled synthesis of AgNP stabilised with PVA[42,53]. Toxicological studies were 
implemented to determine in vitro synergistic cytotoxic effects of AgNP when combined with 
CAP. The results confirmed a dose-dependent reduction in cell viability with the control 
group (PVA-AgNP alone treated U373MG cells) with IC50 of 4.74 µg/ml. Many studies have 
shown AgNPs cytotoxic effect on variety of cancer cells, with all noticeably reporting AgNP 
inducing dose-dependent cytotoxicity including DNA damage and oxidative stress resulting 
in cell death[36–39]. Interestingly as viewed in figure 2a, the combination of AgNP with CAP 
increased more than 100-fold of cytotoxicity in comparison to AgNP treatment alone with 
IC50 of AgNP combined with 25s CAP at 75kV is 0.077 µg/ml and when combined with 40s 
CAP at 75kV, IC50 was 0.0087 µg/ml. Our current group have previously demonstrated the 
synergistic effect of 25-fold of AuNP with CAP on GBM cells, meanwhile the current study 
shows about a 100-fold synergy of the combined therapy with AgNP-CAP[29]. The 
difference in anticancer activities of varying NPs can be explained based on the composition 
such as varying metal properties. AgNPs are known to impart toxicity to cells by efficiently 
producing ROS leading to decreasing mitochondrial function, cell cycle deregulation and 
induction of apoptosis while AuNPs are known for its inertness and have been used in 
imaging from surface-functionalisation, diagnostics and drug delivery[35,54,55]. Although 
both NPs elicit toxicity towards cells, AgNPs famous for their antimicrobial potential and 
production of free radicals is reliant on their internalisation and oxidative nature, leading to 
enhanced cytotoxic events in comparison to AuNPs[56,57]. CAP similarly generates ROS 
and can be localised by selective application process at a milli or micro scale to cancer 
cells[58,59]. Consistent with the findings regarding to oxidative stress correlation to cell 
death with AgNP and CAP continuously mounts the evidence to show that generation of 
ROS is highly related to the mechanism of AgNP and CAP with the results in current study 
showed that the cytotoxicity induced by AgNP alone, as well as the combinational treatment 
AgNP-CAP were efficiently prevented prior NAC treatment up to 10-fold (see Figure 3). The 
results determine that oxidative stress is responsible for the cytotoxicity of AgNPs and CAP, 
which is compliant with previous studies portraying the protective effect of NAC when treated 
with either AgNP or CAP resulting to recovery of proliferative cells[60–63]. Cancer cells 
exists under oxidative stress with elevated levels of ROS than normal cells. Studies have 
shown accumulation of ROS results to cell death causing cancer cells to reach oxidative 
threshold[64]. The beneficial effects of the highly reactive AgNPs other than its composition 
is due to their surface area to volume ratio leading to increase production of ROS within 
cells. ROS are natural by-products of enzymatic and non-enzymatic sources of cellular 
metabolism. It has been published that generation of ROS is also contributed by ionising 
radiation and metal complexes[65]. AgNPs have been reported to have the ability to donate 
electron to molecular oxygen and sets off a cascade of radical forming reactions[66]. Over 
generation of ROS by AgNP have been reported to damage pathological processes such as 
damage to mitochondria, DNA breaks, oxidation of lipids and proteins and apoptosis cell-
induction[67].  
Tseng et al, has previously reported metal nanoparticle fabrication using CAP in the form of 
electric discharge machine, where the generation of arc discharge between two electrodes 
disintegrate silver rod in liquid producing silver nanoparticles[46,68,69]. Due to this 
phenomenon, the current study next investigated the effects of CAP on AgNP physical 
properties. CAP evidently reduced the diameter size of AgNP with longer exposure time in 
presence of reducing agent (see Figure 4a). A study has investigated hydrolysis of NaBH4 in 
aqueous solution, it was reported that the stability of NaBH4 decreases with elevated 
temperature[70–72]. It can be hypothesised with the findings that CAP’s effect on AgNP 
leads to generation of discharge between two electrodes producing a thermal effect on 
AgNP solution with borohydride present, this increases temperature and thus accelerates 
hydrolysis reaction. Furthermore, CAP’s alteration on PVA-AgNP size in our study resulted 
in altered electronic properties on the surface of NP (see figure 4C). Several studies have 
shown size-dependent effects on cytotoxicity using silver nanoparticles[73–75]. In many 
cases, the levels of cell death are increased when smaller nanoparticles are used, and this is 
believed to be due to a larger surface area and enhanced rates of endocytosis. However, the 
effect of size on cytotoxicity in these studies is relatively small (approx. 2-5 fold) and unlikely 
to be solely responsible for the synergistic cytotoxicity between CAP and AgNP observed in 
our study. Many reports stated the standard stable nanoparticle suspension is anything 
higher than positive or negative 30mV. The higher value of positive or negative zeta potential 
has been studied to show in nature to repel each other and not come together. The particles 
tend to aggregate and flocculate with lower zeta potential values due to the absence of 
repulsive forces that hinders agglomeration[76–78]. Studies have reported that the greater 
the negative charge the less toxic the nanoparticles[79,80]. In our study CAP have 
decreased the zeta potential of PVA-AgNP, which may be associated with absence of 
repulsive forces at the double layer leading to the likelihood of agglomeration that can be 
seen in uptake of PVA-AgNP in figure 5. Another reason for the agglomeration of NPs 
evident in the uptake of PVA-AgNP with CAP in figure 5a is due to serum proteins in culture 
media absorbed on NPs surface. Studies have reported the nanoparticle protein corona 
adds complexity to biological system interactions that cannot be limited to electrostatic 
binding alone. The new biological identity of the nanoparticle influences cell behaviour 
interaction[81–83]. 
Nanoparticle detection in cells and tissues are often achieved by employing electron 
microscopy techniques and confocal microscopy to investigate translocation of NPs in 
cells[84–86]. While these techniques have extensively accomplished identification of NPs, 
they lack the potential to validate NPs presence in cells or tissue via spectral mapping. The 
spectral imaging technique provides each pixel of SI image a spectral response for each 
spatial area of a pixel[87]. SI of NPs in cells provides the feasibility of detecting NPs, partial 
size, surface modification, spatial location, presence of NP agglomeration and wavelength 
differentiation[88,89]. In this study, we used SI to asses uptake of PVA-AgNP when exposed 
to CAP resulting to an enhanced PVA-AgNP uptake when cells are exposed to CAP than of 
NP treatment alone. This was quantified using atomic absorption spectroscopy where we 
confirmed a 50-fold increase in Ag/cell following CAP treatment. Our group demonstrated 
the direct and indirect chemical effects generated by CAP DIT-120 is a mediator of the 
uptake increase of AuNPs[29]. Our data here provide further evidence that CAP DIT-120 can 
stimulate uptake of nanomaterials of different sizes and compositions in addition to 
significantly enhancing cytotoxicity. Interestingly, Au/cell is increased by 50% following 
exposure to CAP, whereas Ag/cell is increased 50-fold under similar conditions. This may be 
due to nanomaterial size, the direct effect of CAP on the AgNP or due to a cellular process. 
Further investigation of the biological processes that regulate CAP-stimulated uptake of 
nanomaterials and cytotoxicity in GBM are ongoing and will offer future insights into adapting 
these combinational approaches for development of therapeutics for treatment of GBM and 
other solid tumours. 
In conclusion, the current study reports the enhanced synergistic cytotoxic effect of the 
combined PVA-AgNP and CAP on U373MG cells in vitro. The study showed the ROS-
dependent toxicity of the combined therapy, which was prevented by NAC. Enhanced uptake 
of PVA-AgNP followed by CAP treatment was confirmed using spectral imaging and AAS. 
Overall, the results indicate the effect of CAP on the physical properties of PVA-AgNP 
leading to decrease in nanoparticle size, decrease in surface charge distribution and 
inducing enhanced uptake, aggregation and synergistic cytotoxicity. The findings in the study 
demonstrated the combination therapy of PVA-AgNP with CAP can be further evaluated for 
its potential use in cancer therapy. 
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Highlights 
• Cold Atmospheric Plasma (CAP) triggered a decrease in PVA coated silver nanoparticles 
(PVA-AgNP) size and a change in surface charge distribution.  
• More than 100 fold increase in cytotoxicity of PVA-AgNP was observed in U373MG brain 
cancer cells when combined with subtoxic doses of CAP. 
• Reactive Species necessary for enhanced cytotoxicity.  
• Novel darkfield spectral imaging method used to determine significantly enhanced uptake, 
aggregation and subcellular accumulation of PVA-AgNP following CAP treatment. 
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